Influenza virus resistance to neuraminidase inhibitors: implications for treatment (Q30411822)

21 June 2017

Influenza virus resistance to neuraminidase inhibitors: implications for treatment (English)

1 reference

21 June 2017

Shivanjali Shankaran

1

1 reference

PubMed ID

22249425

21 June 2017

Gonzalo M L Bearman

series ordinal

2

1 reference

21 June 2017

1 April 2012

1 reference

Current infectious disease reports

21 June 2017

1 reference

21 June 2017

14

1 reference

21 June 2017

155-160

1 reference

21 June 2017

2

1 reference

Global epidemiology of influenza: past and present.

21 June 2017

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0236-X

Influenza hemagglutinin and neuraminidase membrane glycoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0236-X

Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0236-X

Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0236-X

Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0236-X

Efficacy and safety of the neuraminidase inhibitor zanamivirin the treatment of influenza A and B virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0236-X

Resistant influenza A viruses in children treated with oseltamivir: descriptive study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0236-X

Oseltamivir resistance and the H274Y neuraminidase mutation in seasonal, pandemic and highly pathogenic influenza viruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0236-X

The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0236-X

Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0236-X

Oseltamivir-resistant influenza A pandemic (H1N1) 2009 virus, Hong Kong, China.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0236-X

A community cluster of oseltamivir-resistant cases of 2009 H1N1 influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0236-X

Systematic review of influenza resistance to the neuraminidase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0236-X

Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0236-X

Outcome of pandemic H1N1 infections in hematopoietic stem cell transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0236-X

Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: A double-blind, randomized, noninferiority clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0236-X

Clinical experience in adults and children treated with intravenous peramivir for 2009 influenza A (H1N1) under an Emergency IND program in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0236-X

Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0236-X

The annual impact of seasonal influenza in the US: Measuring disease burden and costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0236-X

Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0236-X

H1N1 2009 influenza virus infection during pregnancy in the USA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0236-X

Where adults reported receiving influenza vaccination in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0236-X

Generation and characterization of recombinant influenza A (H1N1) viruses harboring amantadine resistance mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0236-X

Emergence and apparent transmission of rimantadine-resistant influenza A virus in families

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0236-X

A point mutation in influenza B neuraminidase confers resistance to peramivir and loss of slow binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0236-X

Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection

21 January 2018

1 reference

12 December 2020

Zanamivir-resistant influenza viruses with a novel neuraminidase mutation

1 reference

12 December 2020

Neuraminidase inhibitors for preventing and treating influenza in healthy adults

1 reference

12 December 2020

Use of oseltamivir in 12 European countries between 2002 and 2007--lack of association with the appearance of oseltamivir-resistant influenza A(H1N1) viruses.

1 reference

12 December 2020

Non-traditional settings for influenza vaccination of adults: costs and cost effectiveness

1 reference

12 December 2020

Estimates of deaths associated with seasonal influenza --- United States, 1976-2007.

1 reference

12 December 2020

Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States

1 reference

12 December 2020

Characteristics of patients with oseltamivir-resistant pandemic (H1N1) 2009, United States

1 reference

12 December 2020

Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration

1 reference

12 December 2020

Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice.

1 reference

12 December 2020

Estimation of influenza vaccine effectiveness from routine surveillance data

1 reference

12 December 2020

Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009.

1 reference

12 December 2020

High frequency of resistant viruses harboring different mutations in amantadine-treated children with influenza

1 reference

12 December 2020

Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season

1 reference

12 December 2020

Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza

1 reference

12 December 2020

Burden of influenza-like illness and effectiveness of influenza vaccination among working adults aged 50-64 years

1 reference

12 December 2020

Vaccines for preventing influenza in healthy adults

1 reference

12 December 2020

10.1007/S11908-012-0236-X

Identifiers

DOI

1 reference

21 June 2017

1 reference

PubMed ID

22249425